Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid
NCT02916641Phase 3Unknown
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Jan 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fuzheng huayu in primary biliary cholangitis (PBC) (2 arms), sponsored by Xijing Hospital of Digestive Diseases. Primary endpoint: Rate of patients with complete biochemical response at 24 weeks. Status: unknown.
02
Drugs
fuzheng huayu
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT02916641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916641.